Haemonetics Stock Surges 17% as CSL Plasma Revives U.S. Supply Deal

Haemonetics (NYSE: HAE) shares jumped more than 17% in August after the medical-technology company disclosed a new non-exclusive U.S. supply agreem
ent with CSL Plasma, marking an important turnaround for a relationship that had previously been a major revenue headwind.

The agreement allows CSL Plasma to use Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposable products for use at U.S. plasma collection centers. Haemonetics disclosed the agreement on August 18 after signing it on August 14. 

The development is strategically important because CSL had previously moved away from Haemonetics' U.S. plasma equipment. The renewed relationship potentially gives Haemonetics another source of equipment and recurring disposable sales while strengthening its position in the U.S. plasma-collection market.

An October 8 update from CSL added more detail: CSL plans to transition a portion of its U.S. plasma collection network to Haemonetics' latest-generation machines, with the rollout expected to reach all of its current U.S. plasma collection centers by the end of 2027. However, the companies have stressed that implementation timing and purchasing volumes remain subject to change.

Why Haemonetics stock jumped 17%

The biggest reason investors reacted so strongly is the history behind the CSL relationship.

In 2021, CSL informed Haemonetics that it did not intend to renew its U.S. supply agreement for Haemonetics' PCS2 plasma collection systems and related disposable kits after the contract expired. At the time, Haemonetics said the CSL agreement generated $117 million of revenue in fiscal 2020, equivalent to 11.8% of total company revenue. 

That business subsequently wound down, creating a significant comparison headwind for Haemonetics.

The new agreement therefore represents more than a normal customer win. It effectively reopens a relationship with one of the world's major plasma collectors.

Investors immediately recognized the potential for CSL to become a meaningful customer again, which helps explain the sharp move in HAE stock.

What CSL will buy from Haemonetics

The agreement covers Haemonetics' NexSys PCS plasma collection system, equipped with Persona PLUS technology, as well as related disposable products.

NexSys PCS is an automated system used for plasmapheresis — the process of collecting plasma from donated blood while returning other components to the donor.

The disposable products are particularly important for the economics of the business.

Unlike a one-time equipment sale, plasma-collection systems can create recurring revenue when customers continue purchasing consumables required to operate the machines. That makes a successful conversion of CSL centers potentially more valuable over time than the initial equipment deployment alone.

Haemonetics' management has emphasized the performance advantages of Persona PLUS. The company previously said the technology can improve plasma yield by a mid-single-digit percentage on average, supported by a randomized clinical trial involving more than 30,000 donations. 

CSL plans a broader rollout by 2027

The latest update makes the deal more significant.

CSL said it plans to transition its U.S. plasma collection network to the latest-generation Haemonetics machines, with the rollout expected to be completed by the end of calendar 2027. CSL's own results presentation described the transition as part of its renewed focus on improving plasma collection efficiency. 

That provides investors with a clearer potential pathway for revenue growth.

However, it is important not to treat the planned rollout as guaranteed revenue.

The Haemonetics agreement is non-exclusive and contains no minimum purchase commitments. The companies have also said that the scope and timing of implementation have not been fully determined. Haemonetics therefore did not immediately change its fiscal 2027 financial guidance. 

This distinction matters because a supply agreement establishes the commercial relationship, but actual revenue will depend on the number of centers converted, the number of machines deployed, disposable consumption and the pace of implementation.

Why the deal matters after CSL's earlier exit

Haemonetics had already been working to reduce its dependence on CSL.

In its fiscal 2026 results, the company said revenue comparisons were being affected by the wind-down of the previous CSL U.S. disposable supply agreement. The company estimated that the portfolio transitions involving the CSL agreement and its Whole Blood business represented approximately $153 million of nonrecurring fiscal 2025 revenue. 

That makes the new agreement particularly interesting.

Haemonetics' underlying plasma business had continued to grow even while the company absorbed the CSL headwind. In its fiscal 2026 guidance, Haemonetics expected 17%–19% organic growth in its Plasma segment excluding the CSL impact. 

The renewed CSL relationship could therefore add another layer of growth on top of a business that was already expanding outside that customer.

The recurring-revenue opportunity

For investors, one of the most important aspects of the deal is the potential for recurring disposable sales.

Medical equipment companies can have very different revenue profiles depending on how much of their business comes from capital equipment versus consumables.

A machine sale can create revenue when the equipment is installed. Consumables, by contrast, can generate revenue repeatedly as the customer continues using the system.

If CSL transitions a large number of U.S. centers to NexSys PCS, the resulting disposable demand could become an important recurring revenue stream for Haemonetics.

But the exact financial contribution is still unknown.

Haemonetics has specifically said it expects to provide an update on the agreement's impact on fiscal 2027 financial results during its second-quarter earnings call in November 2026. 

That earnings update could be a more important catalyst for HAE stock than the original announcement.

CSL also has a reason to improve collection efficiency

The agreement is not simply about Haemonetics winning back a former customer.

CSL is also looking to improve the efficiency of its plasma-collection operations.

CSL's fiscal 2026 materials highlighted a renewed focus on plasma collection efficiency, including continued reductions in collection cost per liter and the transition of part of its U.S. plasmapheresis fleet to newer Haemonetics machines. 

That gives both sides a clear commercial incentive.

CSL wants to collect plasma efficiently because plasma is the raw material used to manufacture therapies such as immunoglobulins. Haemonetics, meanwhile, benefits when more collection centers adopt its equipment and consume its proprietary disposables.

What investors should watch for HAE stock

The headline 17% rally shows how strongly the market views the CSL relationship, but investors should focus on the next set of concrete indicators.

First, rollout speed. The number of CSL centers transitioning to NexSys PCS will determine how quickly the opportunity becomes revenue.

Second, disposable volumes. Recurring consumable purchases could ultimately matter more than the initial equipment placements.

Third, fiscal 2027 guidance. Haemonetics has not yet incorporated the agreement's financial impact into its guidance. Management's November update should provide a clearer picture.

Fourth, margins and cash flow. Haemonetics reported $293 million of operating cash flow and $210 million of free cash flow in fiscal 2026, according to its full-year results. 

Investors will want to see whether additional CSL volume can translate into profitable growth rather than simply higher revenue.

Risks investors should not ignore

The deal is positive, but it is not risk-free.

There are no minimum purchase commitments, meaning the potential revenue opportunity is not fixed. The implementation schedule could also change.

Competition is another factor. Plasma collectors have choices in equipment and technology, and Haemonetics will need to maintain the performance advantages of NexSys PCS and Persona PLUS.

Finally, investors should remember that HAE stock had already appreciated significantly before the CSL announcement. A large portion of the renewed optimism may therefore already be reflected in the valuation.

The bottom line

Haemonetics' stock surge of more than 17% following the CSL Plasma supply announcement reflected the importance of winning back business from a former major customer. The new agreement gives CSL access to NexSys PCS systems with Persona PLUS technology and related disposables across its U.S. plasma collection network. 

The October 8 update makes the opportunity clearer, with CSL targeting completion of the rollout across its current U.S. plasma centers by the end of 2027. But because there are no minimum purchase commitments, investors still need to wait for details on the actual number of machines, timing and financial contribution.

For Haemonetics stock, the key catalyst now is the company's November fiscal 2027 update. That will show whether the CSL agreement can develop from a promising strategic win into a meaningful recurring-revenue opportunity.

Follow the blog for more stock-market, healthcare, medical-technology and business updates.

This article is for informational and educational purposes only and should not be considered investment advice.